Financials in USD. Standardized financial statements.
A compact view of how Ayala Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $13,000 | $250,000 | $3.24M | $253,000 | $2.33M | $6.06M | $12.03M | $3.99M | $0 | $1.00M |
| Revenue Growth? | -94.8% | -92.3% | +1180.6% | -89.2% | -61.5% | -49.6% | +201.2% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $13,000 | $314,000 | $3.71M | $1.28M | $1.28M | $0 | $0 | $0 | $265,390 | $0 |
| Gross Profit? | $0 | -$64,000 | -$468,000 | -$1.03M | $1.05M | $6.06M | $12.03M | $3.99M | -$265,390 | $1.00M |
| Gross Margin? | 0.0% | -25.6% | -14.4% | -407.9% | +44.9% | +100.0% | +100.0% | +100.0% | 0.0% | +100.0% |
| Operating Expenses? | $36.27M | $16.03M | $22.03M | $26.70M | $18.76M | $76.44M | $110.56M | $80.49M | $48.67M | $20.54M |
| Operating Income? | -$36.27M | -$16.09M | -$18.79M | -$26.45M | -$17.71M | -$70.38M | -$98.53M | -$76.49M | -$48.67M | -$19.54M |
| EBITDA? | -$35.87M | -$15.78M | -$18.77M | -$24.39M | -$17.56M | -$72.28M | -$97.43M | -$76.03M | -$48.36M | -$19.29M |
| Income Before Tax | -$51.98M | -$14.31M | -$17.81M | -$26.42M | -$17.49M | -$66.47M | -$97.84M | -$76.09M | -$48.64M | -$18.88M |
| Income Tax Expense | -$3.91M | $50,000 | $50,000 | $50,000 | $306,000 | $50,000 | -$4.40M | -$2.54M | -$1.61M | -$2.36M |
| Net Income? | -$48.07M | -$14.36M | -$17.86M | -$26.47M | -$17.79M | -$66.52M | -$93.44M | -$73.56M | -$47.03M | -$16.53M |
| EPS? | $-7.99 | $-7.90 | $-11.07 | $-34.71 | $-93.60 | $-19.37 | $-34.58 | $-31.17 | $-25.17 | $-14.49 |
| Diluted EPS? | $-7.99 | $-7.90 | $-11.07 | $-34.71 | $-93.60 | $-19.37 | $-34.58 | $-31.17 | $-25.17 | $-14.49 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality